Results 151 to 160 of about 6,404 (193)
A practitioner’s guide to the recombinant zoster vaccine: review of national vaccination recommendations [PDF]
Expert Review of Vaccines, 2021 The adjuvanted recombinant zoster vaccine (RZV) is currently licensed in over 30 countries for the prevention of herpes zoster (HZ) in adults aged ≥50 years. We conducted a review of available national guidelines or recommendations on RZV use to identify the similarities and differences and highlight any potential gaps.
Raunak Parikh, Nicolas Lecrenier
exaly +4 more sources
Effectiveness of the Recombinant Zoster Vaccine for Herpes Zoster Ophthalmicus in the United States [PDF]
Ophthalmology, 2021 To examine the effectiveness of the recombinant zoster vaccine (RZV) for preventing herpes zoster ophthalmicus (HZO) in the general United States population.Retrospective, observational cohort study.Individuals enrolled in the OptumLabs Data Warehouse (OLDW; OptumLabs, Cambridge, MA) who were age eligible for herpes zoster (HZ) vaccination (≥50 years ...
Yuwei Sun +2 more
exaly +7 more sources
Effectiveness of the Recombinant Zoster Vaccine in Adults Aged 50 and Older in the United States: A Claims-Based Cohort Study [PDF]
Clinical Infectious Diseases, 2021 BackgroundThe recombinant zoster vaccine had over 90% efficacy in preventing herpes zoster in clinical trials. However, its effectiveness outside of a clinical trial setting has not been investigated.
Yuwei Sun +2 more
exaly +2 more sources
Open Forum Infectious Diseases, 2022 Approximately 10 years after vaccination with the recombinant zoster vaccine (RZV), an interim analysis of this follow-up study of the ZOE-50/70 trials demonstrated that efficacy against herpes zoster remained high.
Juan CARLOS Tinoco +2 more
exaly +4 more sources
Effectiveness of the recombinant zoster vaccine among Kaiser Permanente Hawaii enrollees aged 50 and older: A retrospective cohort study [PDF]
Vaccine, 2021 BackgroundThe incidence of herpes zoster (HZ) has been on the rise for decades in the United States. Clinical trials for the recombinant zoster vaccine (RZV) demonstrated vaccine efficacy of over 90% in preventing herpes zoster. However, there is limited
Yuwei Sun +2 more
exaly +2 more sources
Estimated Public Health Impact of the Recombinant Zoster Vaccine [PDF]
Mayo Clinic Proceedings Innovations, Quality & Outcomes, 2021 To investigate the potential public health impact of adult herpes zoster (HZ) vaccination with the adjuvanted recombinant zoster vaccine (RZV) in the United States in the first 15 years after launch.We used a publicly available model accounting for national population characteristics and HZ epidemiological data, vaccine characteristics from clinical ...
Brandon J Patterson +2 more
exaly +4 more sources